Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PMN440 (ProMIS Neurosciences)
- Development stage
- Preclinical
- Lead developer
- ProMIS Neurosciences
- Modality
- Vaccines & Immunotherapeutics, Peptides
01
Overview
PMN440 (formerly PMN400) is an investigational therapeutic vaccine being developed by ProMIS Neurosciences for the treatment of synucleinopathies, including Parkinson's disease, multiple system atrophy (MSA), and dementia with Lewy bodies (DLB). Designed using ProMIS's proprietary EpiSelect computational platform, the vaccine consists of computationally-derived conformational B cell epitopes from the EKTKEQ region (amino acids 57-62) of misfolded pathogenic alpha-synuclein. These peptide epitopes are conjugated to keyhole limpet hemocyanin (KLH) and formulated with the saponin-based adjuvant QS-21. PMN440 is engineered to selectively elicit high-affinity antibodies against toxic, misfolded alpha-synuclein oligomers and soluble seeding fibrils, while sparing physiological monomers and non-toxic insoluble fibril deposits, thereby preserving normal alpha-synuclein function and avoiding target distraction.
- Other names
- PMN-400PMN400PMN 400PMN-440PMN440PMN 440alpha-synuclein conformational B cell epitope vaccine
02
Targets
SNCA (Alpha-synuclein)
Beyond the preview
Go deeper on PMN440 (ProMIS Neurosciences).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PMN440 (ProMIS Neurosciences).